行情

CORT

CORT

Corcept医疗
NASDAQ

实时行情|Nasdaq Last Sale

21.49
-0.97
-4.32%
休市 16:00 11/26 EST
开盘
22.22
昨收
22.46
最高
22.60
最低
21.41
成交量
46.90万
成交额
--
52周最高
31.18
52周最低
17.57
市值
24.81亿
市盈率(TTM)
25.62
分时
5日
1月
3月
1年
5年
Trustcore Financial Services, Llc Buys BTC BlackRock Short Maturity Bond ETF, Corcept ...
GuruFocus News · 11/08 15:38
Corcept Therapeutics starts tender offer to repurchase up to 10 million shares
Corcept Therapeutics (NASDAQ:CORT) has added ~7.8% in the pre-market after the company announced the beginning of a tender offer to purchase up to 10M of company common stock par value $0.001 per share.
Seekingalpha · 11/08 14:29
Corcept Therapeutics Announces Commencement of Tender Offer to Purchase up to 10 Million Shares of its Common Stock
MENLO PARK, Calif., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) (“Corcept”) a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders b...
GlobeNewswire · 11/08 13:30
Corcept Therapeutics Launches Tender Offer For Up to 10 Million Shares; Stock Soars
MT Newswires · 11/08 11:12
Corcept's (CORT) Q3 Earnings Beat Estimates, Revenues Miss
Corcept's (CORT) earnings beat estimates in the third quarter of 2021 while revenues miss the same. The company tightens its revenue guidance for 2021.
Zacks · 11/04 13:48
BRIEF-Corcept Therapeutics Q3 GAAP Earnings Per Share $0.24
reuters.com · 11/03 22:22
Corcept Therapeutics (CORT) Q3 Earnings Top Estimates
Corcept (CORT) delivered earnings and revenue surprises of 26.32% and -1.65%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 11/03 22:15
Corcept Therapeutics Q3 Adj. EPS $0.30 Beats $0.20 Estimate, Sales $96.10M Miss $97.19M Estimate
Corcept Therapeutics (NASDAQ:CORT) reported quarterly earnings of $0.30 per share which beat the analyst consensus estimate of $0.20 by 50 percent. This is a 25 percent increase over earnings of $0.24 per share from the
Benzinga · 11/03 21:11
更多
财务预测
实际值(美元)
预测值(美元)
利润表更多
净利润(美元)
同比(%)
资产负债表更多
总资产(美元)
总负债(美元)
资产负债率(%)
现金流表更多
经营现金流(美元)
同比(%)
了解CORT最新的财务预测,通过CORT每股收益,每股净资产,每股现金流等数据分析Corcept医疗近期的经营情况,然后做出明智的投资选择。
分析师评级

4位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

25.00%强力推荐
25.00%买入
25.00%中性
25.00%落后大盘
0.00%卖出
目标价格预测
分析师预测CORT价格均价为24.75,最高价位35.00,最低价为16.00。
最高35.00
均价24.75
最低16.00
现价21.49
EPS
实际EPS
预期EPS
0.060.120.180.24
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
机构持股
总机构数: 308
机构持股: 1.04亿
持股比例: 90.12%
总股本: 1.15亿
类型机构数股数
增持
60
327.62万
建仓
26
62.43万
减持
76
301.47万
平仓
20
62.22万
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
制药
-0.45%
制药与医学研究
+0.44%
高管信息
Non-Executive Chairman/Independent Director
James Wilson
President/Chief Executive Officer/Co-Founder/Director
Joseph Belanoff
Chief Financial Officer/Treasurer
Atabak Mokari
Chief Accounting Officer
Joseph Lyon
Chief Scientific Officer
Hazel Hunt
Other
William Guyer
Other
Sean Maduck
Secretary
Gary Robb
Director
Joshua Murray
Independent Director
Gregg Alton
Independent Director
George Baker
Independent Director
Gillian Cannon
Independent Director
David Mahoney
Independent Director
Kimberly Park
Independent Director
Daniel Swisher
暂无数据
CORT 简况
Corcept Therapeutics Inc.是一家制药公司,从事发现、开发和销售用于治疗严重代谢、精神病和肿瘤疾病的药物。该公司专注于类固醇激素皮质醇相关的疾病。皮质醇的水平升高和异常释放能反应一系列人类疾病。该公司正在开发米非司酮,是一种通过在糖皮质激素受体(GR)上作为竞争性拮抗剂来调节皮质醇作用的化合物。它还发现3个结构上不同的选择性皮质醇调节剂系列,所有这些选择性皮质醇调节剂共享米非司酮对GR的亲和力。与米非司酮不同的是,选择性皮质醇调节剂不结合孕酮受体,因此不终止妊娠或产生与孕酮受体拮抗相关的其它副作用。该公司已经开始从事这些系列的铅化合物的临床前和临床开发业务。

微牛提供Corcept Therapeutics Incorporated(NASDAQ-CORT)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的CORT股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易CORT股票基本功能。